Clinical Trial Update: Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers [Phase 1]

View source ↗

Summary

Phase 1 open-label study assessing pharmacokinetics, safety, and tolerability of a single subcutaneous icatibant dose in healthy Japanese volunteers; completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 1 | Status: COMPLETED | Results posted: 2015-01-14